QNRX — Quoin Pharmaceuticals, Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671502 ·
Israel
Last close
$5.42
Market Cap
$10.89M
52W High
$6.38
52W Low
$3.25
ADV30
19,784
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,131,210 | -4,997,735 | 15,692,891 | 3,124,523 | 6,919,759 |
| Dec 2025 | 0 | — | -4,520,435 | -4,348,373 | 20,390,569 | 3,818,096 | 7,270,663 |
| Sep 2025 | 0 | — | -4,019,925 | -3,948,165 | 6,423,664 | 1,830,906 | 7,638,284 |
| Jun 2025 | 0 | — | -3,793,179 | -3,695,938 | 8,912,589 | 1,668,492 | 6,361,232 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,815,738
Investing CF
$-2,928,861
Financing CF
$18,047,159
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.50
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,968,182
Inventory
—
Receivables
—
ST Investments
$10,918,778
EBIT TTM
$-17,464,749
Pretax Income TTM
$-16,990,211
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,290,716 | -15,804,655 | 20,390,569 | 7,270,663 | — | -13,540,994 |
| Dec 2024 | 0 | -9,528,465 | -8,962,472 | 15,709,338 | 6,504,665 | — | -7,857,309 |
| Dec 2023 | 0 | -9,378,504 | -8,686,573 | 12,169,229 | 6,505,213 | — | -7,864,429 |
| Dec 2022 | 0 | -9,257,704 | -9,381,496 | 14,458,063 | 7,051,289 | — | -8,480,732 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VTGN | Vistagen Therapeutics, Inc. | $10.82M | $0.24 | — |
| ASBP | Aspire Biopharma Holdings, Inc. | $10.95M | $7.81 | — |
| TOVX | Theriva Biologics, Inc. | $10.79M | $0.24 | — |
| BFRG | BullFrog AI Holdings, Inc. | $10.42M | $0.56 | — |
| APRE | Aprea Therapeutics, Inc. | $10.14M | $0.81 | — |
News headlines (Yahoo Finance, 1h cache)
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-08-14 12:30 · Yahoo
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
2026-07-09 12:30 · Yahoo
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
2026-06-30 12:30 · Yahoo
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
2026-06-23 12:30 · Yahoo
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
2026-06-18 12:30 · Yahoo
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
2026-06-16 12:30 · Yahoo
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
2026-06-04 12:30 · Yahoo
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
2026-05-07 12:30 · Yahoo
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
2026-04-30 12:30 · Yahoo
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
2026-04-28 16:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.